Ebv-positive Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Ebv-positive Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas [Phase 2]
Phase 2 study evaluating acalabrutinib plus lisocabtagene maraleucel (Liso-Cel) in refractory/relapsed aggressive B-cell lymphomas, includin…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy [Phase 2]
A Phase 2 clinical trial investigates golcadomide in combination with rituximab as bridging therapy for relapsed or refractory aggressive B-…
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma [Phase 3]
A multicenter, prospective phase 3 randomized study evaluating decitabine added to R-CHOP as initial therapy for EBV-positive diffuse large …
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS [Phase 2]
Phase 2 trial update evaluating Brentuximab Vedotin with R-CHP in newly diagnosed EBV-positive diffuse large B-cell lymphoma, NOS; the study…
-
CLINICAL_TRIALS withdrawal · 2013-07-25Clinical Trial Update: Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly [NA]
A clinical trial evaluating Brentuximab vedotin for CD30-positive EBV-positive diffuse large B-cell lymphoma in elderly patients has been wi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.